Pfizer has completed its acquisition of biopharmaceutical company ReViral. The company develops and markets antiviral drugs for the treatment of respiratory syncytial virus. The most promising of them is sisunatovir, designed to block the fusion of the virus with body cells. The amount of the deal was $525 million.